转移性三阴性乳腺癌患者对trastuzumab-deruxtecan的反应,包括HER2突变和低表达
Caroline Dotto Amarger1, Maria Isabel de Sampaio Rabello1, Sofia Chaves Skaf1
1Faculdade Israelita de Ciências da Saúde Albert Einstein, Hospital Israelita Albert Einstein, São Paulo, Brazil.
Einstein (Sao Paulo, Brazil)
|January 15, 2026
概括
这项案例研究表明,特斯图祖马布德鲁克斯泰干 (T-DXd) 有效治疗了 HER2 低的转移性乳腺癌患者. 精准医学为难以治疗的亚型提供了新的希望.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 乳腺癌是一种普遍的,异构的疾病.
- 精准医学,利用分子分析和向疗法,正在推进瘤治疗.
- 低HER2瘤和抗体-药物联合体 (ADC) 的分类是最近的发展.
研究的目的:
- 报告转移性HER2-低三阴性乳腺癌患者的治疗情况,患者具有特定的HER2突变.
- 评估特拉斯图苏马布德鲁克斯坦 (T-DXd) 作为第三线治疗的疗效.
- 突出精准医学在瘤学中的潜力.
主要方法:
- 一个72岁的妇女患有转移性三阴性乳腺癌的病例报告.
- 患者被归类为具有HER2突变的HER2-低.
- 在标准疗法下疾病进展后,用trastuzumab deruxtecan (T-DXd) 治疗.
主要成果:
- 患者表现出对T-DXd.d的积极反应.
- 患者的无进展生存率超过了临床试验中观察到的中位数.
- 这一结果强调了针对特定瘤形状的向治疗的有效性.
结论:
- 特拉斯图祖马布德鲁克斯泰坎 (T-DXd) 显示出对HER2低转移性乳腺癌的治疗有前途.
- 根据分子形状量身定制的精准医学对于改善结果至关重要.
- 新的治疗选择正在扩大对挑战性癌症亚型的治疗可能性.
更多相关视频
相关概念视频
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K